# A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

> **NCT02770378** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Ulm** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Aprepitant
- **DRUG:** Minocycline
- **DRUG:** Disulfiram
- **DRUG:** Celecoxib
- **DRUG:** Sertraline
- **DRUG:** Captopril
- **DRUG:** Itraconazole
- **DRUG:** Ritonavir
- **DRUG:** Auranofin

## Key facts

- **NCT ID:** NCT02770378
- **Lead sponsor:** University of Ulm
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-10
- **Final completion:** 2020-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-10-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770378, "A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02770378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*